Gentamicin implant - EUSA Pharma/Innocoll
Alternative Names: Cogenzia; CollaRx; Collatamp EG; Collatamp G; Collatamp G topical; Cronocol; Duracoll; Garacol; Garacoll; Garamycin Schwamm; Gentacol; Gentacoll; Gentalyn; Gentimplant; INL-002; Sulmycin Implant; Sulmycin Implant E; Sulmycin SchwammLatest Information Update: 27 Dec 2022
At a glance
- Originator Essex Chemie; Innocoll
- Developer Innocoll; Premier Research Group
- Class Aminoglycosides; Anti-infectives; Antibacterials; Small molecules
- Mechanism of Action Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Postoperative infections
- Phase III Diabetic foot ulcer
Most Recent Events
- 27 Dec 2022 Discontinued - Phase-III for Diabetic foot ulcer (Combination therapy, In the elderly, In adults) in Estonia (Topical)
- 27 Dec 2022 Discontinued - Phase-III for Diabetic foot ulcer (Combination therapy, In the elderly, In adults) in Latvia (Topical)
- 27 Dec 2022 Discontinued - Phase-III for Diabetic foot ulcer (Combination therapy, In the elderly, In adults) in Lithuania (Topical)